Leállítva2. fázis
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
A legfontosabb adatok
- Ki végzi
- University of Leipzig
- Hol
- Németország15 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 38 fő vett részt
- Kezdés
- 2022. jan. 1.
- Befejezés
- 2024. júl. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- CA-4948
- A regiszteradat frissítve
- 2024. augusztus 13.
- Miért állt le
- Prematurely according to trial protocol
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 27 feltétel megnézéseKevesebb
Ki vehet részt
- Diagnosis of de novo myelodysplastic syndrome (MDS) OR de novo myelodysplastic/myeloproliferative neoplasias (MDS/MPN) including MDS/MPN-RS-T, MDS/MPNu, aCML or CMML
- Very low/low/intermediate risk disease: IPSS-R up to 3.5 for MDS; MDS/MPN < 10% bone marrow blasts; for CMML low or intermediate risk according to CPSS-Score
- Symptomatic anemia (based on valid and complete hemoglobin and transfusion history):; NTD (non transfusion dependent): < 3 RBC transfusions and mean hemoglobin level <10 g/dl within the last 16 weeks; LTB (low transfusion burden): 3-7 RBC transfusions within the last 16 weeks in at least two transfusion episodes, maximum 3 in 8 weeks; HTB (high transfusion burden): ≥ 8 RBC transfusions within the last 16 weeks, ≥ 4 in 8 weeks
- Defined transfusion strategy
- No available option of an approved MDS therapy and classification of prior erythropoiesis-stimulating agent (ESA) treatment as follows:; Cohort A: ESA exposed (and refractory or intolerant); Cohort B: ESA naive AND serum erythropoietin level >200 U/L
Ki nem vehet részt
- Inability to swallow and retain oral medications (> 10 pills)
- Prior treatment with azacitidine or decitabine
- Treatment with erythropoiesis stimulating agent (ESA), G-CSF, GM-CSF, lenalidomide, luspatercept and/or another investigational drug or device up to 14 days before registration
- Treatment with iron chelation therapy 56 days before registration, except for subjects on a stable or decreasing dose for at least eight weeks prior to inclusion and during study treatment
- Major surgery within 28 days prior to registration; Concomitant diseases
- Hepatitis virus detectable within 6 months before registration in patients with a history of hepatitis
- Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy that has not resolved to Grade ≤ 1 (except anemia and alopecia)
- Simultaneous participation in another interventional clinical trial or participation in any clinical trial involving administration of an investigational medicinal product within 28 days prior registration
- Known human immunodeficiency virus infection (HIV)
- Active infectious hepatitis (HBV or HCV)
- History of other invasive malignancy, unless definitively treated with curative intent, provided it is deemed to be at low risk for recurrence by the treating physician
- Known allergy or hypersensitivity to any component of the formulation of CA-494824
- Inacceptable organ function; Serum creatinine > 2 × ULN or calculated creatinine clearance < 30 ml/min; AST > 2 × ULN or ALT > 2 × ULN; total bilirubin > 2 × ULN (exception >3 × ULN in patients with documented Gilbert's syndrome); Interfering treatments
- Severe cardiovascular disease (e.g. myocardial infarction within 6 months registration, unstable angina within 6 months registration, NYHA Class III or greater congestive heart failure, serious arrhythmias uncontrolled on treatment, clinically significant pericardial disease, known QTc abnormality > 450 msec on ECG; Formal requirements
- Positive serum pregnancy test in women of childbearing potential
- Age under 18 years at registration
- Compliance with major study procedures
- Patient does not accept bone marrow sampling during screening and after the treatment
- Patient does not accept up to weekly peripheral blood sampling during screening and treatment; Safety
- ECOG performance status ≥ 3
- Women of childbearing potential and men who partner with a woman of childbearing potential unwilling to use highly effective contraceptive methods for the duration of the study and for 90 days after the last dose of CA-4948
- Inability to provide written informed consent
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Anemia in LR-MDS patients
A vizsgálat csoportja
- CA-4948 treatmentEgyéb csoport
Single-arm design. all patients are treated with IMP
Kezelés: CA-4948
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Publikációk
- A regiszteradat frissítve
- 2024. augusztus 13.